43
Participants
Start Date
July 31, 2002
Primary Completion Date
February 29, 2008
Study Completion Date
October 31, 2008
Irinotecan
Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
Panitumumab
Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
5-Fluorouracil
Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
Leucovorin
Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Lead Sponsor
Amgen
INDUSTRY